U.S. regulators on Thursday said they are probing a possible connection between Merck & Co's Singulair asthma drug and suicidal behavior.
Link to Article
MSNBC.com
|
|
||||
|
This Month
Month Archive
|
Thursday, March 27
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:45 PM EDT
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:43 PM EDT
26-Mar-2008 - The pharmaceutical industry has lost confidence in the UK as a place to do business to an "alarming degree" and the situation is only set to deteriorate, reveals new research.
Link to Article in-pharmatechnologist.com
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:42 PM EDT
26-Mar-2008 - Drug regulator Health Canada has published its draft guidelines for pharmaceutical firms seeking to gain approval for biosimilars or "subsequent entry biologics."
Link to Article in-pharmatechnologist.com
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:41 PM EDT
Untitled Document Norwalk, CT (Mar. 12)—The US market for prescription pharmaceuticals grew only 3.8% in 2007, the lowest growth rate in more than 40 years, according to a recent analysis by IMS Health. This is a strong drop in growth from 2006, when the market expanded by 8%. Total US...
Link to Article Pharmaceutical Technology -- Advanstar Communications Inc.
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:39 PM EDT
Untitled Document Washington, DC (Mar. 27)—US Representatives Anna G. Eshoo (D-CA) and Joe Barton (R-TX) introduced legislation this month week to create a regulatory pathway for biosimilars, or follow-on biologics. The so-called Pathway for Biosimilars Act would allow the US Food and Drug Administration to determine “whether the biosimilar is...
Link to Article Pharmaceutical Technology -- Advanstar Communications Inc.
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 27 Mar 2008 11:38 PM EDT
Untitled Document Houston, TX (Mar. 2)—In a press release, the University of Texas announced that Mauro Ferrari, of the University’s Health Science Center at Houston, presented a proof-of-concept study of a new multistage delivery system (MDS) for imaging and therapeutic applications. Ferrari described the study in an article featured in...
Link to Article Pharmaceutical Technology -- Advanstar Communications Inc.
by
Lyle
on Thu 27 Mar 2008 06:53 PM EDT
by
Lyle
on Thu 27 Mar 2008 06:51 PM EDT
by
Lyle
on Thu 27 Mar 2008 06:50 PM EDT
by
Lyle
on Thu 27 Mar 2008 06:49 PM EDT
Officials urge makers of drug-coated device to track patients for up 5 years
Link to Article MSNBC.com
by
Lyle
on Thu 27 Mar 2008 06:45 PM EDT
Meds OK'd right on deadline are 4 times more likely to have major problems
Link to Article MSNBC.com
by
Lyle
on Thu 27 Mar 2008 06:43 PM EDT
Disclosure of $3.6 million in tobacco cash reignites industry influence fears
Link to Article MSNBC.com
by
Lyle
on Thu 27 Mar 2008 06:40 PM EDT
Washington, DC (Mar. 27)—US Representatives Anna G. Eshoo (D-CA) and Joe Barton (R-TX) introduced legislation this month week to create a regulatory pathway for biosimilars, or follow-on biologics. The so-called Pathway for Biosimilars Act would allow the US Food and Drug Administration to determine “whether the biosimilar is interchangeable with the reference product, and gives the FDA the flexibility to determine what clinical testing—if any—is required for approval,” according to a release from Rep. Eschoo.
Link to Article Pharmaceutical Technology
by
Lyle
on Thu 27 Mar 2008 06:38 PM EDT
Norwalk, CT (Mar. 12)—The US market for prescription pharmaceutical grow only 3.8% in 2007, the lowest growth rate in more than 40 years, according to a recent analysis by IMS Health. This is a strong drop in growth from 2006, when the market expanded by 8%.
Link to Article Pharmaceutical Technology
by
Lyle
on Thu 27 Mar 2008 06:37 PM EDT
The US Food and Drug Administration (FDA) appears to be taking a cautious, deliberative approach as it approaches the myriad of scientific and regulatory issues involving nanobiotechnology and nanomedicine. After nearly a year of study, the FDA’s Nanotechnology Task Force is merely recommending the agency study the matter more fully and consider developing guidance for industry to assess the benefits and risks of drugs and medical devices using nanotechnology.
Link to Article Drug Discovery & Development
by
Lyle
on Thu 27 Mar 2008 06:35 PM EDT
26-Mar-2008 - The generic pharmaceutical industry has given short shrift to the latest congressional attempt to construct a viable approval pathway for biosimilars in the US.
Link to Article In-Pharmatechnologist.com
by
Lyle
on Thu 27 Mar 2008 06:31 PM EDT
The revelation that a researcher’s study was underwritten by a tobacco company has caused an appearance of bias.
Link to Article NYTimes.com |
Search
Links
|
||